Biogen Idec and Novo Nordisk both have a potential blockbuster for the treatment of hemophilia A in their pipelines – a market believed to have a potential of just about 30 billion Danish kroner, or 500 million dollars.
With the recent announcement of positive results from a phase III study Biogen edges ahead of its Danish rivals in the race to put a long-acting hemophilia drug on the market first. The study showed that 98 % of bleeding incidents in the trial population could be controlled with one or two injections of Biogen’s rFVIIIFc.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app